Latest quarter update. The company broke out expenses and cost savings. I can't see expense being higher than 10M per quarter, but first quarter will be 8.0m to 8.5M. Good question f8. My figures are for starters and consideration. Just to open your eyes and welcome any insight into them. I believe the Nipent EU will happen and Dacogen approval MDS EU will happen next year.